MX382918B - Proceso para fabricar partículas de resinato de fenilefrina; partículas de resinato de fenilefrina y uso de las partículas de resinato de fenilefrina en formulaciones farmacéuticas. - Google Patents

Proceso para fabricar partículas de resinato de fenilefrina; partículas de resinato de fenilefrina y uso de las partículas de resinato de fenilefrina en formulaciones farmacéuticas.

Info

Publication number
MX382918B
MX382918B MX2017007596A MX2017007596A MX382918B MX 382918 B MX382918 B MX 382918B MX 2017007596 A MX2017007596 A MX 2017007596A MX 2017007596 A MX2017007596 A MX 2017007596A MX 382918 B MX382918 B MX 382918B
Authority
MX
Mexico
Prior art keywords
resin particles
phenylephrine resin
phenylephrine
manufacturing
pharmaceutical formulations
Prior art date
Application number
MX2017007596A
Other languages
English (en)
Other versions
MX2017007596A (es
Inventor
Edward A Koch
Der-Yang Lee
Shun-Por Li
Vincent W Chen
Joel Waldman
Original Assignee
Johnson & Johnson Consumer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer Inc filed Critical Johnson & Johnson Consumer Inc
Publication of MX2017007596A publication Critical patent/MX2017007596A/es
Publication of MX382918B publication Critical patent/MX382918B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen las partículas de fenilefrina adecuadas para formas de dosificación sólidas, semisólidas o líquidas.
MX2017007596A 2014-12-12 2015-12-11 Proceso para fabricar partículas de resinato de fenilefrina; partículas de resinato de fenilefrina y uso de las partículas de resinato de fenilefrina en formulaciones farmacéuticas. MX382918B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462091096P 2014-12-12 2014-12-12
PCT/US2015/065154 WO2016094751A1 (en) 2014-12-12 2015-12-11 Process for manufacturing phenylephrine resinate particles; phenylephrine resinate particles; and use of phenylephrine resinate particles in pharmaceutical formulations

Publications (2)

Publication Number Publication Date
MX2017007596A MX2017007596A (es) 2018-03-09
MX382918B true MX382918B (es) 2025-03-13

Family

ID=55130033

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007596A MX382918B (es) 2014-12-12 2015-12-11 Proceso para fabricar partículas de resinato de fenilefrina; partículas de resinato de fenilefrina y uso de las partículas de resinato de fenilefrina en formulaciones farmacéuticas.

Country Status (13)

Country Link
US (2) US20160166518A1 (es)
EP (1) EP3229787A1 (es)
JP (2) JP6720174B2 (es)
KR (1) KR20170095939A (es)
CN (2) CN115068425A (es)
AU (1) AU2015360386B2 (es)
BR (1) BR112017012400A8 (es)
CA (1) CA2969473A1 (es)
HK (1) HK1245155A1 (es)
MA (1) MA41152A (es)
MX (1) MX382918B (es)
RU (1) RU2727204C2 (es)
WO (1) WO2016094751A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3039920A1 (en) 2016-10-10 2018-04-19 Rhodes Pharmaceuticals L.P. Pharmaceutical resinate compositions and methods of making and using thereof
AU2018347991A1 (en) 2017-10-09 2020-05-07 Rhodes Pharmaceuticals L.P. Pharmaceutical resinate compositions and methods of making and using thereof
CN113384521B (zh) * 2020-03-12 2023-03-28 中国科学院上海高等研究院 一种快速增溶去甲肾上腺素水溶液且有效抑制样品氧化的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990332A (en) 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
PT946145E (pt) 1996-12-20 2008-10-17 Mcneil Ppc Inc Fármacos antitússicos libertados por resinas de troca iónica
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US9492541B2 (en) 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US8343546B2 (en) 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
KR101495146B1 (ko) * 2006-03-16 2015-02-24 트리스 파마 인코포레이티드 약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제
US20070231387A1 (en) * 2006-04-04 2007-10-04 Luigi Levi Film-coated solid dosage forms
CN101505735A (zh) 2006-06-01 2009-08-12 先灵公司 用于持续释放去氧肾上腺素的药用组合物
NZ573174A (en) 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
BRPI0719021A2 (pt) * 2006-11-21 2013-12-17 Mcneil Ppc Inc Suspensões analgésicas de liberação modificada.
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US8282957B2 (en) 2008-06-26 2012-10-09 Mcneil-Ppc, Inc. Coated particles containing pharmaceutically active agents
WO2010115015A1 (en) * 2009-04-03 2010-10-07 Coating Place, Inc. Modified-release pharmaceutical drug composition
US20130230587A1 (en) * 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
EP2726066B1 (en) * 2011-06-28 2021-03-31 Neos Therapeutics, LP Dosage forms of amphetamine for oral administration
BR112014019526B8 (pt) 2012-02-07 2022-08-30 Chenango Zero Llc Forma de dosagem de liberação rápida e seu método de produção
US20140271892A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles having good auc
US20140271891A1 (en) 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles and use thereof in pharmaceutical formulations

Also Published As

Publication number Publication date
AU2015360386A1 (en) 2017-06-15
JP2020125344A (ja) 2020-08-20
MX2017007596A (es) 2018-03-09
BR112017012400A2 (pt) 2018-04-24
CA2969473A1 (en) 2016-06-16
US20210330614A1 (en) 2021-10-28
JP2017537132A (ja) 2017-12-14
JP6720174B2 (ja) 2020-07-08
JP7016907B2 (ja) 2022-02-07
RU2017124229A3 (es) 2019-04-16
US20160166518A1 (en) 2016-06-16
WO2016094751A1 (en) 2016-06-16
CN106999433A (zh) 2017-08-01
CN115068425A (zh) 2022-09-20
EP3229787A1 (en) 2017-10-18
HK1245155A1 (zh) 2018-08-24
AU2015360386B2 (en) 2021-02-25
KR20170095939A (ko) 2017-08-23
BR112017012400A8 (pt) 2022-08-09
MA41152A (fr) 2017-10-17
RU2017124229A (ru) 2019-01-15
RU2727204C2 (ru) 2020-07-21

Similar Documents

Publication Publication Date Title
HUE049341T2 (hu) Szubsztituált indazolok, eljárás ezek elõállítására, ezeket tartalmazó gyógyszerkészítmények, valamint ezek alkalmazása gyógyszerkészítmények elõállítására
BR112016030787A2 (pt) entidade química, composição farmacêutica e seu uso
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
BR112016016158A2 (pt) Derivados de heterociclila bicíclicos como inibidores de irak4, sua composição farmacêutica e seus usos
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
BR112017003219A2 (pt) formulação de acetato de abiraterona e métodos de uso
CL2015002897A1 (es) Inhibidores de bace1
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
DK3236935T3 (da) Farmaceutisk doseringsform til anvendelse på slimhinder
IL251770B (en) Granules of an active substance with a double taste masking technique, a method for their production and orally disintegrating tablets containing them
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
IL262568A (en) Protein based excipient for active pharmaceutical ingredients
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EP3459369A4 (en) PHARMACEUTICAL COMPOSITION WITH LACTOBACILLUS SP. KCCM 11826P STRAIN FOR PREVENTING HYPERPHOSPHATMA AND TREATING CHRONIC KIDNEY DISEASE AND HEALTH FUNCTIONAL FOOD
MX382918B (es) Proceso para fabricar partículas de resinato de fenilefrina; partículas de resinato de fenilefrina y uso de las partículas de resinato de fenilefrina en formulaciones farmacéuticas.
BR112018005299A2 (pt) 1,1-difeniletilenos substituídos com alquenilfenoxi, processos para sua preparação e seu uso
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
MX2015012340A (es) Partículas de resinato de fenilefrina.
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
MX2015012542A (es) Partículas de resinato de fenilefrina y su uso en formulaciones para productos farmacéuticos.